3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Head and Neck Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Breast Neoplasms
2
Zollinger-Ellison Syndrome
1
Uterine Cervical Dysplasia
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Neoplasms
1
Obesity
1
Mouth Neoplasms
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Inflammation
1
Gastrinoma
1
Colorectal Neoplasms
1
Chemotherapy Effect
1
Burkitt Lymphoma
1
Interventions
Docetaxel
137
Prednisone
120
Abiraterone Acetate
91
Leuprolide
86
enzalutamide
84
Radiotherapy
59
bicalutamide
56
Magnetic Resonance Spectroscopy
54
Goserelin
54
Androgen Antagonists
51
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
47
apalutamide
44
abiraterone
34
Radiosurgery
31
Specimen Handling
30
gallium 68 PSMA-11
29
Gonadotropin-Releasing Hormone
29
cabazitaxel
28
Carboplatin
27
darolutamide
25
Estramustine
24
luprolide acetate gel depot
23
relugolix
22
Metformin
22
Triptorelin Pamoate
20
sipuleucel-T
19
radium Ra 223 dichloride
19
Radiation
19
pembrolizumab
18
deltacortene
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Prostatic Neoplasms
×
Omeprazole
×
Clear all
NCT04337580
2026-04-13
FASN
Wake Forest University Health Sciences
Phase 2
Recruiting
50 enrolled